U.S. House panel to examine approval, pricing of Alzheimer's drug from Biogen

 A U.S. House panel said on Friday it would examine the approval and pricing of Biogen Inc's Alzheimer's drug, Aduhelm.

Biogen had announced a list price of $56,000 per year for the drug.

https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-nbsp-U-S-House-panel-to-examine-approval-pricing-of-Alzheimer-s-drug-from-Biogen-35705085/